PHILADELPHIA, PA—For high-risk patients with heterozygous familial hypercholesterolemia (HeFH), a novel therapy that shuts off the PCSK9 gene can lower LDL cholesterol, early data from the heart-1 ...
Soy Nómada on MSN
One-Time' Injection Could End High Cholesterol; New Study Stuns
A groundbreaking new study reveals a gene-editing therapy that dramatically lowered 'bad' cholesterol in monkeys, offering ...
Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the ...
The FDA has set out its reasons for putting Verve Therapeutics’ high cholesterol gene editing therapy on hold. Officials want additional data to allay concerns that patients could pass on the edited ...
Results Validate In Vivo Liver DNA Base Editing as a Once-and-Done Approach to Treat Coronary Heart Disease by Lowering of LDL Cholesterol and PCSK9 Protein Levels CAMBRIDGE, Mass.--(BUSINESS ...
A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...
Because identical twins develop from a single fertilized egg, they have the same genome, the entire set of genetic material found in an organism. So, any differences between them, even in traits with ...
Eli Lilly and Company is acquiring Verve Therapeutics, Inc. for $1B upfront plus a $3/share CVR upon milestone being met, driven by promising gene-editing therapies for ASCVD. VERVE-102, a one-time IV ...
PHILADELPHIA -- A DNA base editing therapy, intended for lifelong lowering of LDL cholesterol, passed initial tests in people with severe, advanced atherosclerotic cardiovascular disease (ASCVD).
In a few months, a daring clinical trial may fundamentally lower heart attack risk in the most vulnerable people. If all goes well, it will just take one shot. Verve’s CEO, Dr. Sekar Kathiresan, took ...
iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to ...
DURHAM – Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies. The agreement also gives iECURE a license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback